Group 1: Investor Relations Activities - The investor relations activity was conducted via an online platform on September 12, 2025, from 15:00 to 16:00 [2] - Key participants included the Chairwoman Zhang Caihong, General Manager Dou Yan, and Financial Director Wu Yunfeng [2] - The company addressed various investor questions during the earnings briefing [2] Group 2: Product Development and R&D - The planning project department has established a dedicated R&D team of 6 personnel, focusing on the "Polypropylene Plant Liquid Catalyst Injection System Process Development" project [2] - The project aims to optimize product structure and enhance product variety through research on polymerization processes and catalyst dosage [2] Group 3: Production Capacity and Utilization - The company is currently operating all major production facilities as planned, with specific capacity utilization rates to be disclosed in regular reports [3][4] - The isobutylene hydrogenation unit has been expanded to a capacity of 35,000 tons/year [5] Group 4: Financial Performance and Growth Strategy - The company aims to enhance its core competitiveness by improving the C5/C9/propylene industrial chain and transitioning products towards functional, specialized, and high-end applications [3] - In 2024, the company invested in a 10,800 tons/year butadiene extraction unit, which has already been put into production [5] - The company is exploring new business areas to mitigate risks associated with its 100% revenue reliance on the chemical business [5] Group 5: Asset Management - The pharmaceutical division's assets were unsuccessfully listed for sale in 2017 and 2025, with plans to seek potential buyers in the future [6]

Group 1: Company Operations and Projects - The demolition of the Cangzhou Landmark Pearl Textile City on August 19 does not involve the listed company's business, and the funds belong to the parent company [2] - The Cangzhou BOPA film project is expected to be operational by October 2025, with ongoing construction [2] - The company is actively monitoring and promoting the progress of its expansion projects to ensure timely production [2][3] Group 2: Market and Product Demand - The new energy storage action plan aims for a national installed capacity of over 180 million kilowatts by 2027, driving direct investment of approximately 250 billion yuan [3] - The company's lithium-ion battery separator products are used in various applications, including new energy vehicles and household appliances, which are expected to see increased demand [3][6] - The company has not raised prices for dry and wet membrane products compared to the first half of the year [6] Group 3: Shareholder and Market Concerns - The company is committed to timely share cancellation procedures as required [3] - Concerns were raised about the second largest shareholder's frequent selling of shares, which may impact the company's stock price [4][5] - The company emphasizes its independence from the controlling shareholder and maintains a robust corporate governance structure [5][6] Group 4: Financial Performance and Strategy - The company is focused on enhancing its market presence and expanding its revenue through domestic and international market development [5][6] - The management is exploring effective ways to maintain company value, including stable dividend policies and stock buybacks [4] - The company has not considered mergers or acquisitions to strengthen its competitive position at this time [4][5] Group 5: Future Outlook and Challenges - The company acknowledges the competitive challenges in the nylon membrane market and is working on strategies to improve its market position [6][7] - There are no current plans to extend product lines into solid-state batteries or to produce skeleton membranes [4][6] - The company is committed to improving its operational efficiency and management capabilities to enhance overall performance [6][7]

Group 1: Company Overview - The company specializes in the production and sales of ultra-fine fiber synthetic leather, PU synthetic leather, optical-grade PMMA, and MS products, as well as hazardous waste disposal services [2][3] - It is a leading enterprise in the optical-grade PMMA/MS and synthetic leather industries in China, with four wholly-owned subsidiaries [2][3] Group 2: Production Capacity and Financial Performance - The current production capacity for optical-grade PMMA is 155,000 tons, with 80,000 tons from Suzhou and 75,000 tons from Chongqing; MS capacity is 75,000 tons [3] - The company achieved over 50 million yuan in revenue from MS products in the first half of the year, and the optical materials segment contributed over 100 million yuan in profit [3][4] Group 3: Product Sales and Market Growth - The export sales of optical-grade PMMA products exceeded 10 million USD in the first half of the year, driven by improved product quality and the closure of some foreign competitors' PMMA factories [4] - The company’s ultra-fine fiber products in Chongqing saw a net profit increase of over 30 million yuan compared to the same period last year [4] Group 4: Future Growth and Strategic Focus - High-end products such as MS, modified/dyed PMMA, and specialty esters are identified as key growth drivers for future performance [4] - The company aims to enhance its industry chain advantages by maintaining stable upstream supply of MMA and expanding its high-end product market share [4]

Group 1: Company Performance - The company reported stable production and operations, with specific performance details to be disclosed in the upcoming Q3 2025 report [1] - The company holds a 46.15% stake in Jiangyin Yuande Venture Capital Partnership, which has a 2.04% stake in the recently listed Jiyuan Group, indicating a potential impact on company performance [2] Group 2: Fund Utilization - Currently, the company has ongoing projects funded by raised capital, including a 10MW/20MWh energy storage project and a project for producing 12,000 tons of biodegradable non-woven fabric annually [1] - Unallocated raised funds are kept in a special account, with detailed usage reported on August 27, 2025 [2] Group 3: Employee Stock Plan - The employee stock ownership plan for 2025 has a grant price set at 7.86 CNY per share [2] Group 4: Future Investments - The company currently has no plans for investments in artificial intelligence [2] Group 5: Disclosure Compliance - The investor relations activity did not involve any undisclosed significant information [2]

Group 1: Investor Relations Activities - The investor relations activities took place from August 27 to September 12, 2025, including multiple strategy meetings and site visits with various investment firms [10][11]. - A total of 45 participants attended the first strategy meeting on August 27, with subsequent meetings attracting 6, 30, 9, and 12 participants respectively [2][3][4][5]. - The largest strategy meeting on September 5 had 65 participants, indicating strong interest from investors [6]. Group 2: Financial Performance - In the first half of 2025, the company's general automation business achieved revenue of approximately 8.8 billion CNY, representing a year-on-year growth of 17%, significantly outpacing the industry growth of 1% [11]. - The company's market share for mid-to-large PLC products is approximately 5.1%, ranking sixth in the Chinese market, with expectations for further growth [11][12]. Group 3: Product Development and Strategy - The company plans to invest 8% to 10% of its revenue in R&D to maintain technological leadership, focusing on software, overseas market products, and humanoid robotics [14]. - The iFA platform aims to provide integrated automation solutions, reducing costs and time for industrial clients [13]. - The company is actively developing components for humanoid robots, including motors and actuators, to meet market demands [15]. Group 4: Elevator Business Outlook - The elevator business is considered mature, with strategies to enhance market share among multinational clients and expand overseas [16][17]. - The company is focusing on providing comprehensive elevator solutions, including control systems and maintenance services, to capitalize on the growing demand in the after-service market [17].

证券代码：000889 证券简称：中嘉博创 中嘉博创信息技术股份有限公司投资者关系活动记录表 编号：2025-01 投资者关系活动 类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 投资者网上提问 时间 2025 年 9 月 15 日(周一) 下午 14:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 员姓名 1、董事长兼董事会秘书 吴鹰 2、总裁兼财务总监 李鹏宇 投资者关系活动 主要内容介绍 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、还记得您 23 年接待日的发言，仲裁这些事情拖的太久了， 还是希望公司聚焦自身的发展，通信行业还是有很多可能 的。希望越来越好，相信领导的能力 尊敬的投资者，您好！感谢您的长期关注与信任！公司始终 铭记股东期待，后续公司将持续落实发展规划，争取以更好的经 营成果回报信任。 2、中嘉博创呢，公司仲裁有完没完 ...

Group 1: Financial Performance and Debt Management - The company reported a net profit of 250 million yuan in the first half of the year, with the basic materials segment contributing 180 million yuan and the new materials segment contributing 70 million yuan [4] - The company emphasizes debt management, ensuring short-term debt is manageable through stable sales returns and sufficient bank credit lines [2] - Current liabilities are covered by liquid assets, indicating a reasonable debt situation and controllable liquidity risks [2] Group 2: Strategic Planning and Market Position - The company is expanding its production capacity with projects like the annual production of 50,000 tons of high-precision copper alloy strips and 60,000 tons of high-precision copper alloy rolling strips, expected to be operational by the end of the year [8] - The company is actively involved in the AI and semiconductor sectors, with products applicable in data communication and server cooling materials [2] - The company is focusing on high-end product transformation, gradually phasing out low-margin products to enhance profitability [3] Group 3: Subsidiary Developments and Market Engagement - The subsidiary, Jiangsu Xinhai High导, is a key player in the copper-based materials market, supplying to major companies like Leoni and Fos Group [2] - The company is in the feedback stage for the IPO of its subsidiary, Top Technology, which is involved in critical materials for the semiconductor industry [3] - The company is exploring strategic partnerships to strengthen its market position and enhance its operational capabilities [3] Group 4: Market Challenges and Stock Performance - The company's stock performance has been under pressure, with concerns about potential shareholder sell-offs impacting market confidence [3] - The company is implementing measures such as share buybacks and dividends to stabilize its market value and boost investor confidence [3] - The company is monitoring copper price fluctuations closely, employing hedging strategies to mitigate risks associated with raw material price volatility [7]

Group 1: Business Performance Overview - In the first half of 2025, the company achieved operating revenue of ¥782,503,879.30 and a net profit attributable to shareholders of ¥5,325,109.51, indicating a turnaround in profitability and a stable business outlook [1] - The three main business sectors of the company are developing synergistically, contributing to the overall positive performance [1] Group 2: Commercial Operations - The commercial operations focus on a "supermarket + asset leasing + management output" model, covering regions such as Hainan, Guangdong, and others [1] - The company is enhancing its business model by integrating fresh food procurement, instant retail, and community services, leveraging the Greater Bay Area policies [1] - The "Xingyue Mall" has undergone brand upgrades and operational improvements, with a 11% year-on-year increase in total foot traffic [1] Group 3: Trade Logistics - The trade logistics business is driven by a dual focus on "logistics + commerce," creating a comprehensive logistics park that integrates agricultural product collection, warehousing, and cold chain services [2] - The company operates over 700,000 square meters across five collection and distribution centers, enhancing the rural revitalization and consumption upgrade strategies [2] Group 4: Commodity Trade - The commodity trade business leverages the company's supply chain to connect with producers, agents, and e-commerce platforms, focusing on fresh produce, beverages, and daily necessities [2] Group 5: Asset Upgrades in Xi'an - The company initiated a 34,000 square meter renovation of the Minsheng Department Store, aiming to create an interactive consumer space [2] - The "Xingyue Mall" (formerly Minsheng Luomashi Shopping Center) completed a 16,000 square meter space renovation, introducing over 40 unique brands and creating a diverse consumption ecosystem [2]

Group 1: Financial Performance - In the first half of 2025, the company reported a revenue of 1.489 billion yuan, a year-on-year decrease of 18.86% [2] - The net profit for the same period was 257 million yuan, down 42.90% compared to the previous year [2] - Basic earnings per share were 0.4813 yuan, reflecting a decline of 42.90% year-on-year [2] - The weighted average return on net assets was 5.99%, a decrease of 5.63% year-on-year [2] Group 2: Product Overview Refrigeration Products - The company offers a diverse range of refrigeration products, including commercial central air conditioning compressors, frozen and refrigerated compressors, and heat pump compressors [3] - These products are widely used in commercial buildings, food cold chain logistics, and heating applications, catering to various customer needs [3] - The company has seen growth in screw and magnetic levitation centrifugal compressors used in data center cooling [3] Air Compression Products - The air compressors serve as core equipment in engineering machinery and are crucial in industries such as pharmaceuticals, chemicals, electronics, and road maintenance [3] - The company is expanding its market presence in oil-free air compressors, which have significant potential in industries requiring high air quality, such as food and biomedicine [3] Vacuum Products - The vacuum products are primarily used in the photovoltaic and semiconductor industries, with plans to expand into lithium batteries, pharmaceuticals, and other sectors [4] - The company has begun small-scale supply to domestic chip manufacturers, indicating a growing recognition of its vacuum products [4] - Although the current contribution to overall performance is limited, the accelerating domestic semiconductor industry presents a promising growth opportunity for the company [4] Group 3: Investor Relations Activity - The investor relations activity took place from September 8 to September 12, 2025, at the company's premises [2] - Participants included various investment firms and individual investors, indicating a broad interest in the company's performance and products [2] - The company confirmed that no undisclosed significant information was shared during the activity [5]

Group 1: Innovation Drug Development - The company is optimistic about the future of China's innovative drug market, with a record-breaking overseas transaction amount in 2025 [2] - The company has multiple products in critical clinical trial stages and is committed to accelerating innovation pipelines [3] - The company’s R&D investment accounts for 43% of revenue, significantly exceeding industry standards, yet revenue from biopharmaceuticals is only 0.94 billion [5] Group 2: Financial Management and Cash Flow - The company reported a net cash outflow of 1.235 billion, but has 455 million in idle funds for financial management [3] - The company maintains a low-risk investment strategy for idle funds to support R&D and operational activities [3] - The caffeine business has a global market share exceeding 50%, but revenue has declined due to a 20% drop in export prices [5] Group 3: Market Strategy and Competition - The company’s product, Enlansumab, has entered the insurance reimbursement list, with ongoing commercialization efforts [10] - The company faces intense competition in the PD-1 market, with an average annual price drop exceeding 20% [10] - The company is exploring various strategies to maintain gross margins in the face of price drops due to centralized procurement [8] Group 4: Future Plans and Strategic Direction - The company aims to transform into an innovative drug company, leveraging its strong cash flow from functional raw materials to support R&D [5] - The company plans to enhance its core competitiveness in the biopharmaceutical sector and achieve profitability in its innovative drug segment [9] - The company is actively utilizing national policies to promote innovative development [7]